(Q34722477)

English

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

Europe PubMed Central

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

2

object named as

R N Brogden

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

author name string

J C Gillis

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

publication date

1 March 1995

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

467-484

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of infection in colonic surgery by rifaximin. A controlled, prospective, randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bile rifaximin concentration after oral administration in patients undergoing cholecystectomy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The crisis in antibiotic resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ambulatory medical treatment of colonic diverticulitis. An open clinico-endoscopic-histological study with rifaximin, a nonaminoglycoside enteric antibiotic

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic effectiveness of L 105, given in three pediatric formulations, as an intestinal antibacterial agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro activity of rifaximin and rifampicin against some anaerobic bacteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifaximin, a rifamycin derivative for use in the treatment of intestinal bacterial infections in seriously disabled patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infectious diarrhea in the aged: controlled clinical trial of rifaximin

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progress in the treatment of portal-systemic encephalopathy (PSE).

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-absorbable antibiotics in the treatment of diverticular disease of the colon

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifaximin (L/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medical progress. Diverticular disease of the colon

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical Pharmacokinetics of Rifampicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of chronic hepatic encephalopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history of diverticular disease of the colon

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progress in the treatment of chronic portasystemic encephalopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[The rifaximin therapy and prophylaxis of episodes of acute diverticulitis].

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open study on the antidiarrhoeal effectiveness of the L 105 compound

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A non-absorbable rifamycin for treatment of hepatic encephalopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antimicrobial Prophylaxis for Appendectomy and Colorectal Surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifaximine versus neomycin in the treatment of portosystemic encephalopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of Rifaximin in the treatment of acute diarrhoeal enteritis: open study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4-Deoxypyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of hepatic encephalopathy with non-absorbable antibiotics

1 reference

https://pubmed.ncbi.nlm.nih.gov/7774516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199549030-00009

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34722477&oldid=2196979589"